Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies.

There is compelling rationale for manipulating the microbiota to treat inflammatory bowel diseases (IBDs). Although studies of animal models of intestinal inflammation produced promising results, trials in humans have been disappointing. In contrast to IBD, the role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been considered, but early stage results have been encouraging. As pharmaceutical companies develop fewer truly novel agents for treatment of these disorders, consumers seek safer, long-term strategies to deal with chronic symptoms. We assess the rationale for modulating the microbiota for treatment of IBD and IBS, and discuss whether current concepts are simplistic and overstated or simply under-researched. Are claims exaggerated and expectations unrealistic? Difficulties with microbiota terminology and technologies, as well as differences among patients and the heterogeneity of these diseases, pose additional challenges in developing microbiota-based therapies for IBD and IBS.

[1]  L. Bird.  Neuroimmunology: Bugs on the brain , 2015, Nature Reviews Immunology.

[2]  Liyuan Tao,et al.  [A meta-analysis of probiotics for the treatment of irritable bowel syndrome]. , 2015, Zhonghua nei ke za zhi.

[3]  L. Brandt,et al.  An overview of fecal microbiota transplantation: techniques, indications, and outcomes. , 2013, Gastrointestinal endoscopy.

[4]  T. Dinan,et al.  Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut , 2013, Gut microbes.

[5]  C. Manichanh,et al.  Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet , 2013, Gut.

[6]  B. Naliboff,et al.  Consumption of fermented milk product with probiotic modulates brain activity. , 2013, Gastroenterology.

[7]  P. Moayyedi,et al.  Helicobacter pylori infection in functional dyspepsia , 2013, Nature Reviews Gastroenterology &Hepatology.

[8]  E. Quigley,et al.  Bugs on the brain; brain in the gut—seeking explanations for common gastrointestinal symptoms , 2013, Irish Journal of Medical Science.

[9]  F. Shanahan.  The colonic microbiota in health and disease , 2013, Current opinion in gastroenterology.

[10]  F. Shanahan.  A commentary on the safety of probiotics. , 2012, Gastroenterology clinics of North America.

[11]  T. Dinan,et al.  Probiotics in transition. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  F. Shanahan,et al.  The gut microbiota—a clinical perspective on lessons learned , 2012, Nature Reviews Gastroenterology &Hepatology.

[13]  Samuel I. Miller,et al.  The Microbiome and Inflammatory Bowel Disease: Is There a Therapeutic Role for Fecal Microbiota Transplantation? , 2012, The American Journal of Gastroenterology.

[14]  Y. Belkaid,et al.  Acute Gastrointestinal Infection Induces Long-Lived Microbiota-Specific T Cell Responses , 2012, Science.

[15]  K. Whelan,et al.  Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease , 2012, Alimentary pharmacology & therapeutics.

[16]  Ian B. Jeffery,et al.  The microbiota link to irritable bowel syndrome , 2012, Gut microbes.

[17]  F. Shanahan.  The microbiota in inflammatory bowel disease: friend, bystander, and sometime-villain. , 2012, Nutrition reviews.

[18]  C. Lam,et al.  An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome , 2012, Journal of neurogastroenterology and motility.

[19]  H. Sokol,et al.  Increase in fecal primary bile acids and dysbiosis in patients with diarrhea‐predominant irritable bowel syndrome , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[20]  Armando Villarreal,et al.  Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. , 2012, WMJ : official publication of the State Medical Society of Wisconsin.

[21]  Marcus J Claesson,et al.  An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota , 2011, Gut.

[22]  R. Sartor,et al.  Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[23]  Andrea J Pruijssers,et al.  Intestinal Microbiota Promote Enteric Virus Replication and Systemic Pathogenesis , 2011, Science.

[24]  John A. Todd,et al.  Metagenomics and Personalized Medicine , 2011, Cell.

[25]  E. Quigley.  Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. , 2011, Gastroenterology clinics of North America.

[26]  J. Cryan,et al.  The microbiome‐gut‐brain axis: from bowel to behavior , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[27]  W. Chey,et al.  Rifaximin therapy for patients with irritable bowel syndrome without constipation. , 2011, The New England journal of medicine.

[28]  C. Bernstein,et al.  Association Between the Use of Antibiotics in the First Year of Life and Pediatric Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[29]  F. Shanahan.  Probiotics in perspective. , 2010, Gastroenterology.

[30]  John E. Scott,et al.  Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme , 2010, Science.

[31]  E. Quigley.  Probiotics in Gastrointestinal Disorders , 2010, Hospital practice.

[32]  M. Frisch,et al.  Antibiotic use and inflammatory bowel diseases in childhood , 2010, Gut.

[33]  R. Xavier,et al.  Virus-Plus-Susceptibility Gene Interaction Determines Crohn's Disease Gene Atg16L1 Phenotypes in Intestine , 2010, Cell.

[34]  J. Versalovic,et al.  Probiotics-host communication , 2010, Gut microbes.

[35]  P. Scully,et al.  25 Early-Life Dysbiosis Leads to Visceral Hypersensitivity in Adulthood , 2010 .

[36]  M. Jiang,et al.  Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. , 2010, World journal of gastroenterology.

[37]  A. Cheifetz,et al.  Meta‐analysis: targeting the intestinal microbiota in prophylaxis for post‐operative Crohn’s disease , 2010, Alimentary pharmacology & therapeutics.

[38]  F. Shanahan.  Gut Microbes: From Bugs to Drugs , 2010, The American Journal of Gastroenterology.

[39]  A. Cheifetz,et al.  Interventions for prevention of post-operative recurrence of Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[40]  S. Nikfar,et al.  Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. , 2009, Diseases of the colon and rectum.

[41]  James Versalovic,et al.  Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. , 2009, Gastroenterology.

[42]  M. Helmrath,et al.  A new animal model of postsurgical bowel inflammation and fibrosis: the effect of commensal microflora , 2009, Gut.

[43]  P. Scully,et al.  Early Life Stress Alters Behavior, Immunity, and Microbiota in Rats: Implications for Irritable Bowel Syndrome and Psychiatric Illnesses , 2009, Biological Psychiatry.

[44]  Tao Zhou,et al.  Meta‐analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease , 2009, Internal medicine journal.

[45]  P. Whorwell,et al.  Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN‐173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation , 2009, Alimentary pharmacology & therapeutics.

[46]  P. Moayyedi,et al.  The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review , 2008, Gut.

[47]  A. Andriulli,et al.  Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome: A Multicenter, Randomized Study , 2008, Journal of clinical gastroenterology.

[48]  S. Nikfar,et al.  A Meta-Analysis on the Efficacy of Probiotics for Maintenance of Remission and Prevention of Clinical and Endoscopic Relapse in Crohn’s Disease , 2008, Digestive Diseases and Sciences.

[49]  W. Chey,et al.  The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review , 2007, The American Journal of Gastroenterology.

[50]  B. Flourié,et al.  Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[51]  E. Quigley.  Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management , 2007, Journal of digestive diseases.

[52]  C. Hawkey,et al.  Probiotics for maintenance of remission in Crohn's disease. , 2006, The Cochrane database of systematic reviews.

[53]  W. Khan,et al.  Gut motor function: immunological control in enteric infection and inflammation , 2006, Clinical and experimental immunology.

[54]  G. Brandi,et al.  Interactions Between Commensal Bacteria and Gut Sensorimotor Function in Health and Disease , 2005, The American Journal of Gastroenterology.

[55]  A. Zinsmeister,et al.  A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating , 2005, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[56]  Z. Tulassay,et al.  Probiotics for gastrointestinal disorders , 2004, Drug and therapeutics bulletin.

[57]  A. Zinsmeister,et al.  A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea‐predominant irritable bowel syndrome , 2003, Alimentary pharmacology & therapeutics.

[58]  Henry C. Lin,et al.  Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome , 2000, American Journal of Gastroenterology.

[59]  M. Yamauchi,et al.  Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. , 1999, The American journal of physiology.

[60]  F. Guarner,et al.  Stimulation of transforming growth factor beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. , 1998, Gastroenterology.

[61]  S. Collins.  The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. , 1996, Gastroenterology.

[62]  W. Whitehead,et al.  Irritable bowel syndrome , 1980, Digestive Diseases and Sciences.

[63]  G. Macfarlane,et al.  Bacteria, colonic fermentation, and gastrointestinal health. , 2012, Journal of AOAC International.

[64]  A. Zinsmeister,et al.  FUNCTIONAL BOWEL DISORDERS , 2007, The American Journal of Gastroenterology.

[65]  T. Midtvedt,et al.  The role of the gastrointestinal microflora in postsurgical adhesion formation--a study in germfree rats. , 1992, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.